Compare Dollar General Corp. (DG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Mesoblast Limited — how do they compare? Dollar General Corp. trades at $124.27 (market cap $26.95B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Dollar General Corp. is far larger — about 14.9× Mesoblast Limited's market cap, and Dollar General Corp. pays a 1.93% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Mesoblast Limited for 14 Days on average.
| DG | MESO | |
|---|---|---|
Market Cap | $26.95B | $1.81B |
Volume | 1,654,929 | 240,620 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $20.96 |
52-Week Low | $95.94 | $13.19 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $41.13B | $1.89B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $124.27, up 0.82% on the day, with a neutral technical signal and bearish moving average trend. The stock shows strong valuation metrics with a P/E of 15.86 and P/S of 0.62, while recent earnings have consistently beaten estimates. Revenue growth is steady, reaching $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart.
The outlook is cautiously optimistic, supported by analyst consensus price target of $137.27 (10.5% upside) and a 55.77% buy rating. Key opportunities include margin recovery initiatives and digital growth, while risks involve competitive pressures and consumer spending volatility. The stock presents a value opportunity with upside potential if execution improves.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
